New sustained-release antihypertensive selected as government-funding R&D project

Published: 2003-08-18 06:57:00

Updated: 2003-08-18 06:57:00

The Small and Medium Business Administration recently announced that a new sustained-release antihypertensive, which has been co-developed by Kolmar Korea and DDSTech, was selected as one of the government-funding R&D projects.

The SMBA noted that a total of 356 million won will be injected t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK